SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
SGMO
--
0.00%
--
Sangamo teams up with Novartis in neurodevelopmental disorders
Sangamo Therapeutics (NASDAQ:SGMO) will collaborate with Novartis (NYSE:NVS) to develop and commercialize gene regulation therapies to treat neurodevelopme
seekingalpha · 3d ago
Sangamo Therapeutics shares are trading higher after the company announced a global collaboration with Novartis to develop genomic medicines for autism and other neurodevelopmental disorders. Sangamo will receive a $75 million upfront payment and is eligible to receive up to $720 million in potential milestones.
Benzinga · 4d ago
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders; Sangamo Will Receive A $75M Upfront; Eligible To Receive Up To $720M In Potential Milestones
Benzinga · 4d ago
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targ
Business Wire · 4d ago
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market closes on Wednesday, August 5, 2020. The press release will be follo
Business Wire · 4d ago
Sangamo Therapeutics (SGMO) Earnings Expected to Grow: Should You Buy?
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4d ago
4 More Biotechs Break From IPO Starting Gate
GuruFocus.com · 6d ago
Here's Why Biogen Just Blew Its Q2 Earnings Out of the Water
MotleyFool.com · 07/25 04:00
Freeline Therapeutics Aims For $100 Million U.S. IPO
Seeking Alpha - Article · 07/23 19:05
How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Do Institutions Own?
Simply Wall St. · 07/09 12:43
3 Top Biotech Stocks to Watch in July
These three stocks are positioned for growth -- but investors must tread carefully in the short term.
Motley Fool · 07/09 11:31
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of
Benzinga · 06/24 12:11
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.
Business Wire · 06/24 12:00
HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $14
HC Wainwright & Co. maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and lowers the price target from $16 to $14.
Benzinga · 06/22 10:51
Hedge Funds Are Getting Crazy About Sangamo Therapeutics, Inc. (SGMO)
Insider Monkey · 06/19 17:22
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
Reuters · 06/18 14:44
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Business Wire · 06/18 14:00
Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial
MotleyFool.com · 06/18 04:00
Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock?
Zacks · 06/16 13:36
Edited Transcript of SGMO.OQ earnings conference call or presentation 11-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/16 03:40